Guerbet - Visibly different for over 100 years
For more than a century, Guerbet has been a key player in medical imaging. We are pushing the boundaries of diagnostics and interventional radiology thanks to the expertise and commitment of our teams.
Innovation at the heart of our DNA
Pioneers since 1901 with Lipiodol®, we have made our mark on the history of radiology with world-leading contrast agents (Dotarem®, Elucirem®, Xenetix®) and AI solutions that enable earlier and more accurate diagnoses.
An independent, family-owned company on a human scale
As a French company with a presence on five continents, we cultivate close relationships and trust with healthcare professionals. Millions of patients around the world benefit from medical examinations performed using Guerbet products.
Rooted in our history, focused on tomorrow
With 100 years of expertise, we continue to innovate in the service of more accessible, personalized, and humane medicine.
Join our symposia
📅 Wednesday, March 4th
🕛 11:30 PM CET
📍 Room G2, Level -2
Speakers: Dr. Jean-Sébastien Raynaud (France),
Dr. Imran Shahid (United Kingdom),
Dr. Sarah Catoen (France)
Chairperson : Prof. Valérie Vilgrain (France)
📅 Friday, March 6th
🕛 12:30 PM CET
📍 Room G2, Level -2
Speakers: Dr. Emilio Inarejos (Spain),
Dr. Thorsten Bley (Germany),
Chairperson: Dr. Josep Munuera (Spain)
Supporting pediatric imaging
Discover on our booth exclusive pediatric MRI insights to overcome specific challenges while prioritizing safety.
Join us on Linktree
Discover our ECR 2026 highlights, book a slot to explore real-world clinical cases, and access educational resources.
Products & Solutions Highlights with Intrasense
Oncological innovation with DUOnco™
A collaboration dedicated to innovation.
Born from the strategic partnership between Guerbet and Intrasense https://intrasense.fr/en/, DUOnco™ is a range of autonomous AI solutions dedicated to oncological imaging. Our goal: to detect bone, pancreatic and hepatic lesions, in order to improve patient care.
DUOnco™ Pancreas: detect earlier, treat better.
Among the new solutions presented at JFR, DUOnco™ Pancreas illustrates the potential of AI in oncology.
Pancreatic cancer is one of the most complex to diagnose at an early stage, while early detection can significantly improve survival outcomes.
DUOnco™ Pancreas enables radiologists to:
- automatically detect and segment pancreatic lesions,
- analyze the main pancreatic duct,
- prioritize results across three levels,
- automatically transfer information to RIS/PACS.
With a sensitivity of 93%, this solution is designed to help identify subtle lesions at an earlier stage.
DUOnco™ Pancreas, DUOnco™ Bone, and DUOnco™ Liver, Class II medical devices, are developed, manufactured, and distributed by Intrasense SA. DUOnco™ Pancreas is software designed to facilitate the analysis and examination of contrast-enhanced CT images containing the pancreas, through the automatic detection and measurement of focal pancreatic lesions and the main pancreatic duct. DUOnco™ Liver, DUOnco™ Bone, and DUOnco™ Pancreas bear the CE 0459 marking in accordance with the requirements of Regulation 745/2017 on medical devices. These medical devices are not approved by the FDA. DUOnco™ is a medical device, not covered by insurance, and is intended for use by healthcare professionals only. Precautions for use must be followed; consult the instructions for use for more information. Intrasense® and DUOnco™ are either registered trademarks or trademarks of Intrasense SA or Guerbet in France and/or other countries.
I26004180 - February 2026